Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries
暂无分享,去创建一个
D. Cummings | A. Azman | S. Cauchemez | M. O’Driscoll | Gabriel Ribeiro Dos Santos | Lin Wang | J. Paireau | A. Fontanet | H. Salje | Gabriel Ribeiro Dos Santos | Megan O’Driscoll | Gabriel Ribeiro dos Santos | Gabriel Ribeiro Dos Santos
[1] S. Leeder,et al. A population based study , 1993, The Medical journal of Australia.
[2] Benjamin J Cowling,et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Mark Jit,et al. Projecting social contact matrices in 152 countries using contact surveys and demographic data , 2017, PLoS Comput. Biol..
[4] J. Lessler,et al. Estimating the burden of SARS-CoV-2 in France , 2020, Science.
[5] F. Yu,et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset , 2020, European Respiratory Journal.
[6] Are SARS-CoV-2 seroprevalence estimates biased? , 2020, The Journal of infectious diseases.
[7] B. Greenhouse,et al. Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? , 2020, The Journal of Infectious Diseases.
[8] N. Hens,et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples , 2020, medRxiv.
[9] M. Poljak,et al. Low prevalence of active COVID-19 in Slovenia: a nationwide population study of a probability-based sample , 2020, Clinical Microbiology and Infection.
[10] S. Bhatt,et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe , 2020, Nature.
[11] Jens K. Boldsen,et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] C. Reusken,et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak , 2020 .
[13] Jose L. Paniagua,et al. Infection fatality risk for SARS-CoV-2: a nationwide seroepidemiological study in the non-institutionalized population of Spain , 2020 .
[14] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.
[15] Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York , 2020, Annals of Epidemiology.
[16] Bruce Guthrie,et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study , 2020, The Lancet Global Health.
[17] C. Whittaker,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[18] Jens K. Boldsen,et al. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors , 2020, medRxiv.
[19] P. Klenerman,et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure , 2020, medRxiv.
[20] Jian-min Jin,et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality , 2020, Frontiers in Public Health.
[21] Mayte SanmartÃn Jose L. Pérez-Olmeda. A Population-Based Seroepidemiological Study of SARS-CoV-2 in Spain (ENE-COVID) , 2020, Social Science Research Network.
[22] David R. Holtgrave,et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York , 2020, Annals of Epidemiology.
[23] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.
[24] E. Dong,et al. An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.
[25] S. Bhatt,et al. Have deaths from COVID-19 in Europe plateaued due to herd immunity? , 2020, The Lancet.
[26] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[27] R. Krüger,et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. , 2020, medRxiv.
[28] Jose L. Paniagua,et al. SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study , 2020, medRxiv.